These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 20539909)

  • 21. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM
    Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Novel oral anticoagulants: focus on stroke prevention and treatment of venous thrombo-embolism.
    Steffel J; Braunwald E
    Eur Heart J; 2011 Aug; 32(16):1968-76, 1976a. PubMed ID: 21421599
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New oral anticoagulants and their implications for dental patients.
    O'Connell JE; Stassen LF
    J Ir Dent Assoc; 2014; 60(3):137-43. PubMed ID: 25080640
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of the oral direct factor Xa inhibitor - betrixaban.
    Palladino M; Merli G; Thomson L
    Expert Opin Investig Drugs; 2013 Nov; 22(11):1465-72. PubMed ID: 23964817
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rivaroxaban for the prevention and treatment of venous thromboembolism.
    Turpie AG
    Fundam Clin Pharmacol; 2012 Feb; 26(1):33-8. PubMed ID: 21851388
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oral anticoagulation with Factor Xa and thrombin inhibitors: Is there an alternative to warfarin?
    Zikria J; Ansell J
    Discov Med; 2009 Dec; 8(43):196-203. PubMed ID: 20040270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change.
    Zikria JC; Ansell J
    Curr Opin Hematol; 2009 Sep; 16(5):347-56. PubMed ID: 19550318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.
    Mantha S; Ansell J
    Thromb Haemost; 2012 Sep; 108(3):476-84. PubMed ID: 22740145
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Novel oral anticoagulation in management of venous thromboembolism, atrial fibrillation, and acute coronary syndrome.
    Khemasuwan D; Suramaethakul N
    Clin Appl Thromb Hemost; 2012 Sep; 18(5):476-86. PubMed ID: 22387584
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases.
    Turpie AG
    Arterioscler Thromb Vasc Biol; 2007 Jun; 27(6):1238-47. PubMed ID: 17379841
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Newer anticoagulants in cardiovascular disease: a systematic review of the literature.
    Maan A; Padmanabhan R; Shaikh AY; Mansour M; Ruskin JN; Heist EK
    Cardiol Rev; 2012; 20(5):209-21. PubMed ID: 22370770
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New oral anticoagulants in atrial fibrillation.
    Turpie AG
    Eur Heart J; 2008 Jan; 29(2):155-65. PubMed ID: 18096568
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tissue factor-mediated activation of the prothrombin complex concentrate (PCC) is differently inhibited by dabigatran, rivaroxaban, and apixaban: potential clinical implication.
    Sadeghi N; Kahn D; Jeske W; Hoppensteadt D; Fareed J
    Clin Appl Thromb Hemost; 2013; 19(6):589-99. PubMed ID: 23463187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dabigatran etexilate: a possible replacement for heparinoids and vitamin K antagonists?
    Guay DR
    Hosp Pract (1995); 2011 Feb; 39(1):105-25. PubMed ID: 21441766
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Novel oral anticoagulants.
    Khoo CW; Tay KH; Shantsila E; Lip GY
    Int J Clin Pract; 2009 Apr; 63(4):630-41. PubMed ID: 19222611
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dabigatran for stroke prevention in atrial fibrillation: the RE-LY trial.
    Paikin JS; Haroun MJ; Eikelboom JW
    Expert Rev Cardiovasc Ther; 2011 Mar; 9(3):279-86. PubMed ID: 21438804
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Direct inhibitors of coagulation proteins - the end of the heparin and low-molecular-weight heparin era for anticoagulant therapy?
    Laux V; Perzborn E; Heitmeier S; von Degenfeld G; Dittrich-Wengenroth E; Buchmüller A; Gerdes C; Misselwitz F
    Thromb Haemost; 2009 Nov; 102(5):892-9. PubMed ID: 19888525
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New oral anticoagulants in development: potential for improved safety profiles.
    Bauer KA
    Rev Neurol Dis; 2010; 7(1):1-8. PubMed ID: 20410856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical management of rivaroxaban-treated patients.
    Palareti G; Ageno W; Ferrari A; Filippi A; Imberti D; Pengo V; Rubboli A; Toni D
    Expert Opin Pharmacother; 2013 Apr; 14(5):655-67. PubMed ID: 23414291
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.